June - 2020

MECFA Blog

Second-hand Smoke Affects Metabolism in Infants and Children with CF, Study Finds

Exposure to second-hand smoke in infants and children with cystic fibrosis (CF) is linked to changes in levels of metabolites and...

Cystic Fibrosis and Herpes Are Not the Same Thing

I don’t have herpes. I need to clarify this. I don’t have herpes, or Hep C, or cancer, even though many seem to think I do. Although I...

4DMT Receives Up to $14M from CFF for Development of Customized Gene Carrier

After being given more than $3 million from the Cystic Fibrosis Foundation (CFF) in 2017 to expand the development of viral vectors for...

Bacterial 'Death Stars' could be tricked into destroying themselves

Researchers have discovered a network of channels inside bacterial communities which could be used to kill bacteria more quickly by...

Kalydeco Approved in Europe to Treat Children with R117H Mutation

The European Commission has approved Vertex’s Kalydeco (ivacaftor) for the treatment of children and adolescents with cystic fibrosis...

Suppressing Function of Chloride Channel TMEM16A Eyed as Potential Therapeutic Approach

Researchers have reported the case of two siblings with impaired CFTR function due to a deficiency in another chloride channel, called...

Microbe DNA Discovery May Lead to Noninvasive Test for CF Infections

People with cystic fibrosis (CF) have higher levels of DNA from common microbes that cause CF-related infections circulating in their...

Real-world Use of Kalydeco for CF Highly Effective, Large-scale Analysis Shows

Kalydeco treatment led to fewer deaths, transplants, hospitalizations, and exacerbations in people with cystic fibrosis (CF) compared to...

Pharmac funds new cystic fibrosis medicine

New treatment for cystic fibrosis is on the horizon, one that will help young children suffering from the disorder digest their food more...

Eurordis Urges Expansion of Newborn Screening Initiatives Across Europe

European authorities must step up efforts to screen babies for a multitude of genetic disorders, a panel of experts suggested during a...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p